Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial.

Research output: Contribution to journalArticle


The use of mammalian target of rapamycin (mTOR) inhibitors have been limited by adverse events (AE), including delayed wound healing. We retrospectively reviewed all AE and serious AE (SAE) in The Scandinavian heart transplant (HTx) everolimus (EVE) de novo trial with early calcineurin (CNI) avoidance (SCHEDULE). The aim of the study was to compare wound complications between EVE and CNI based regimen.


  • Mitra Rashidi
  • Sorosh Esmaily
  • Arnt E Fiane
  • Einar Gude
  • Kim A Tønseth
  • Thor Ueland
  • Finn Gustafsson
  • Hans Eiskjær
  • Göran Rådegran
  • Göran Dellgren
External organisations
  • Oslo university hospital
  • Sahlgrenska University Hospital
  • University of Oslo
  • Copenhagen University Hospital
  • Aarhus University Hospital
  • Skåne University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cardiac and Cardiovascular Systems
Original languageEnglish
Pages (from-to)80-84
JournalInternational Journal of Cardiology
Publication statusPublished - 2016
Publication categoryResearch